Knowledge HQ

The G-Rex® Grant Program is empowering CGT manufacturers with resources and expertise and is a $20 million initiative by ScaleReady, Wilson Wolf Manufacturing, Bio-Techne, and CellReady, that is designed to propel the advancement of cell and gene therapies (CGT).  If you’re engaged in pre-clinical research, process development, or cGMP manufacturing of cell and gene-modified cell therapies, this program is for you!

Review the official description and outline of the new G-Rex® Grant Program, which empowers CGT manufacturers with resources and expertise. This $20 million initiative by ScaleReady, Wilson Wolf Manufacturing, Bio-Techne, and CellReady is designed to propel the advancement of cell and gene therapies (CGT).

Aliquot accuracy whitepaper provides an in-depth look at how the Cue® Cell Processing System ensures consistency and quality in cell therapy products.

ExCellerate NK Media offers a robust and versatile solution for NK cell cultures, designed to transition from research to clinical application seamlessly.

This is our proven process illustrating how ScaleReady works in a true partnership with your T and NK cell therapy program to enable the successful commercialization of your drug. This is a linear left-to-right, as well as a holistic view, of how at every stage, we look to simplify, streamline, and scale by offering expertise and support for your cell therapy program. Through our proven process, we deliver practical and viable solutions by providing the most simple, scalable, and versatile manufacturing products. Our process is proven, as our products are represented in approved CAR-T drugs around the globe.

GMP Recombinant Human IL-2 joins IL-7 and IL-15 produced within Bio-Techne’s dedicated animal-free GMP facility located in St. Paul MN USA. Our GMP-grade IL-2 contains the same cysteine to serine mutation found in Proleukin®. This mutation has been reported to prevent cysteine mispairing in E.coli, which can lead to protein aggregation and makes our new GMP-grade IL-2 protein soluble in injectable-grade water.

IL-2, IL-7, and IL-15 are critical cytokine components to many successful T and NK cell therapy programs.  Choosing these cytokines from a partner that can offer seamless translation from RUO to GMP means that the consistency across lots, the confidence in bioactivity, and cost-effectiveness are no longer barriers to manufacturing with consistency, translating with speed and scaling without limitation.  Learn more about these powerhouse cytokines in this brochure.

Key features of the Cue Cell Processing System include flexibility - user-defined aliquot container number and fill volume, all-in-one - ability to concentrate and wash in the same procedure as final formulate and fill, precision - aliquot volumes ≤10 mL, and control - optional automated temperature control and mixing.

Whether you’re focused on early-stage trials or ramping up to full commercialization, Lovo’s spinning membrane filtration technology enables fast, precise, and flexible procedures that help increase your lab’s overall operational efficiency and processing consistency without compromising product quality.

The benefits of non-viral gene engineering, when compared with its viral counterpart, offer simplicity, and streamlined capabilities all while lowering risk and cost. TcBuster as part of the ScaleReady portfolio empowers cell therapy programs to move to market faster and with superior scalability ensuring confidence in reproducibility, bench to bedside.